Prof. James Larkin summarizes key factors guiding patient selection for treatment with PD-1 inhibitors and evaluates the current clinical value of prognostic and predictive biomarkers, including PD-L1 and emerging biomarkers, in melanoma.1/3 Next Interview
Prof. Reinhard Dummer reviews the mechanistic rationale underpinning anti-PD-1-based treatment regimens in melanoma before appraising the latest clinical data surrounding emerging novel treatment strategies incorporating PD-1 inhibitors with new and existing agents, alongside their potential impact on treatment sequencing options in future.2/3 Next Interview
Prof. Caroline Robert explores the long-term impact of PD-1 blockade in melanoma and contextualizes factors informing treatment discontinuation decisions to highlight the critical importance of the patient–physician dynamic in optimizing the patient journey through the immuno-oncology treatment landscape in melanoma.3/3 Take CME Test
Overview & Learning Objectives
In this activity, leading dermato-oncology experts explore the impact of immune checkpoint inhibition with PD-1 blockade on the treatment landscape and patient experience in melanoma.
This activity has been jointly provided by Oakstone and touchIME IMMUNOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
This activity is designed to meet the educational needs of oncologists, and in particular, dermato-oncologists specializing in skin cancer, dermatologists, primary care physicians, nurses, pharmacists and other HCPs worldwide involved in the treatment and care of patients with melanoma.
Prof. James Larkin discloses: Consultancy fees from Achilles, AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Ipsen UltraGenyx, Imugene, Incyte, iOnctura, Kymab, Merck Serono, Merck Sharp & Dohme, Nektar, Novartis, Pierre Fabre, Pfizer, Roche/Genentech, Secarna, Vitaccess.
Prof. Reinhard Dummer discloses: Consultancy and/or advisory board fees from Alligator, AmGen, Bristol-Myers Squibb, Catalym, Merck Sharp & Dohme, Novartis, Pierre Fabre, Regeneron, Roche, Sanofi, Second Genome, Sun Pharma, Takeda.
Prof. Caroline Robert discloses: Consultancy fees from Biothera, Bristol-Meyers Squibb, CureVac, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity.
Walter Murray Yarbrough, MD has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™️. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AME). European physicians interested in converting 0.5 AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Date of original release: 6 January 2021. Date credits expire: 6 January 2022.
After watching this touchEXPERT OPINIONS, you should better be able to:
- Discuss factors to consider when selecting PD-1 inhibitors to treat melanoma
- Understand the rationale for combination regimens incorporating PD-1 blockade
- Analyse the role of long-term clinical and real-world data in informing treatment decisions